Persistent Systems Ltd

Q2 FY25 Earnings Call Analysis

IT - Software

Full Stock Analysis
fundraise: No informationcapex: No informationrevenue: Category 3margin: Category 2orderbook: Yes
💰

fundraise

Any current/future new fundraising through debt or equity?

- There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript/pages. - The company has not discussed raising new capital via debt or equity in the recent earnings call or disclosures. - Focus remains on operational growth, margin improvement, large deal pipelines, and cautious cost management. - Debt, cash, and investments appear stable, with total cash and investments at Rs. 307.8 million as of June 30, 2025. - No forward-looking statements indicate plans for external fundraising at this time.
🏗️

capex

Any current/future capex/capital investment/strategic investment?

- The transcript does not explicitly mention specific current or future capex (capital expenditures) plans. - Persistent Systems is focusing on strategic investments primarily in AI capabilities and platform development, including their generative AI-powered digital engineering platform, SASVA 3.0. - The company acquired Arrka last year, which strengthened their Digital Trust Layer capabilities integrated across platforms like SASVA, iAURA, and GenAI Hub. - Investment is also being made in talent transformation and building AI-enabled workforce, highlighted by organizational changes such as hiring a new Chief Marketing Officer and Chief People Officer. - There is mention of maintaining investments in SG&A and operational initiatives, implying ongoing strategic spend to support growth. - No detailed capex or capital investment figures or plans are disclosed within the provided transcript.
📊

revenue

Future growth expectations in sales/revenue/volumes?

- Persistent Systems is confident of continuing growth across key verticals, targeting top-quartile growth in the sector. - The BFSI (Banking, Financial Services and Insurance) segment is expected to lead growth for the year, followed by high-tech and healthcare life sciences. - Healthcare vertical will continue to grow, though not at the elevated rates of the past year; no further degrowth expected. - The company aims to reach a $2 billion revenue run-rate by the end of FY27. - Pipeline and order book remain healthy, though decision-making is cautious due to macroeconomic factors. - Larger deals are in the pipeline, creating potential upside in future sales. - Revenue conversion focuses on ACV from multi-year deals, illustrating steady contractual growth. - Management remains prudent, deferring wage hikes to navigate current uncertainties. - No specific forward-looking guidance numbers given, but overall outlook is positive with continued investment in AI capabilities and sales channels.
📈

margin

Future growth expectations in earnings/operating earnings/profits/EPS?

- Persistent Systems aims to reach a $2 billion revenue run rate by the end of FY27, indicating strong growth expectations. - EBIT margin is expected to improve by 200-300 basis points by FY27 from ~15% in Q1 FY26. - ESOP costs, which impacted margins recently, are expected to remain flat before gradually reducing in FY27. - Revenue growth is expected to be led by BFSI, followed by software high-tech and healthcare life sciences verticals, all projecting growth. - Trailing 12-month attrition and other costs are being managed prudently to support margin expansion. - EPS grew 36.5% YoY in Q1 FY26; continued profit growth reflects operational leverage and better collections. - Persistent maintains a confident stance on margin trajectory with operational efficiency and pricing initiatives driving future profits. - No specific forward guidance provided on quarterly earnings, but the overall tone is confident in achieving top-quartile industry growth.
📋

orderbook

Current/ Expected Orderbook/ Pending Orders?

- Total Contract Value (TCV) for Q1 FY26 stood at USD 520.8 million. - New bookings contributed TCV of USD 337.0 million. - Annual Contract Value (ACV) of this TCV is USD 385.3 million. - ACV from new bookings contributed USD 211.8 million. - Management is reasonably confident about the growth journey and executable order book. - Pipeline and order book are described as healthy despite a cautious market environment. - Longer decision-making cycles noted, requiring a larger pipeline to maintain bookings. - No specific forward-looking guidance given on order book growth, but larger deal pipelines are present. - Management will let future quarters unfold before giving concrete updates on order book and deal wins.